Skip to main content

ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders

Given the progress of its clinical trials, and its latest quarterly financials, Zynerba appears to be an excellent buy-and-hold investment consideration.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.